Kairos Pharma (KAPA) Free Cash Flow (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Free Cash Flow came in at -$805000.0 in Q2 2025, down 379.17% YoY from $288358.2 in Q2 2024, and down 12.75% on a QoQ basis from -$714000.0 in Q1 2025.
Kairos Pharma (KAPA) Free Cash Flow (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Free Cash Flow data on file, last reported at -$805000.0 in Q2 2025.
- Quarterly Free Cash Flow fell 379.17% year-over-year to -$805000.0 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$3.3 million (up 16.01% YoY) and the FY2025 annual result came in at -$3.4 million, up 13.0% from the prior year.
- Free Cash Flow retreated to -$805000.0 in Q2 2025, from -$714000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $66000.0 in Q4 2023 to a low of -$2.0 million in Q3 2024.
- A 3-year average of -$772571.4 and a median of -$714000.0 in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 2831.82% — and 2025, when it tumbled 379.17%.
- Tracing KAPA's Free Cash Flow over 3 years: stood at $66000.0 in 2023, then tumbled by 2831.82% to -$1.8 million in 2024, then soared by 55.35% to -$805000.0 in 2025.
- The last three Free Cash Flow figures came in at -$805000.0 (Q2 2025), -$714000.0 (Q1 2025), and -$1.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -805,000.00 |
| Jun 30, 2025 | -805,000.00 |
| Mar 31, 2025 | -714,000.00 |
| Mar 31, 2025 | -714,000.00 |
| Dec 31, 2024 | -1.80 Mn |
| Dec 31, 2024 | -1.80 Mn |
| Sep 30, 2024 | -2.02 Mn |
| Sep 30, 2024 | -2.02 Mn |
| Jun 30, 2024 | -168,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Dec 31, 2023 | 66,000.00 |
| Dec 31, 2023 | 66,000.00 |